+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multifunctional effects of honokiol as an anti-inflammatory and anti-cancer drug in human oral squamous cancer cells and xenograft

Multifunctional effects of honokiol as an anti-inflammatory and anti-cancer drug in human oral squamous cancer cells and xenograft

Biomaterials 53: 274-284

The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44). Griess assay, zymography, and quantitative PCR were performed to study iNOS expression and subsequent nitric oxide (NO) production in OSCC cell lines. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic analysis was used to elucidate the proteins associated with ER stress and cellular cytotoxic response induced by HK. Pull-down assay and molecular modeling were performed to better understand how HK interacts with ERp44. In vitro and in vivo experiments in which ERp44 expression was knocked down were performed to better understand the effects of ERp44 on a cellular level and anti-cancer effects of HK. Expression levels of iNOS and subsequent NO secretion were reduced in OSCC cell lines treated with HK. ERp44 was significantly decreased in OSCC cell lines by HK treatment. HK directly bound to ERp44, and ERp44 knock-down significantly inhibited oral cancer cell proliferation and colony formation. Moreover, HK treatment effectively inhibited tumor growth and ERp44 levels in BALB/c nude mice bearing HN22 cell xenografts. Our findings suggest that HK inhibited inflammation and induced apoptosis by suppressing both iNOS/NO and ERp44 expression in HN22 and HSC4 cells and xenograft tumors, and thus could be a potent anti-inflammatory and anti-cancer drug candidate for human oral cancer treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 058357967

Download citation: RISBibTeXText

PMID: 25890726

DOI: 10.1016/j.biomaterials.2015.02.091

Related references

Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1. International Journal of Oncology 43(4): 1103-1110, 2014

Anti-proliferative effects on human colon cancer cells of combined treatment with cationic liposome-entrapped human interferon-beta or gamma gene and anti-cancer drug. Journal of Clinical Biochemistry & Nutrition 23(2): 77-83, 1997

Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells. Acta Biochimica et Biophysica Sinica 45(9): 773-779, 2014

Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells. Cancer Epidemiology 35(3): 272-278, 2011

The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Research 62(4): 1004-1007, 2002

Anti-cancer drug sensitivity test against human testicular cancer xenograft--comparison with clinical results of chemotherapy. Hinyokika Kiyo. Acta Urologica Japonica 34(11): 1903-1909, 1988

Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft. Oncology Reports 28(6): 2188-2194, 2013

Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer. Oncology Reports 28(2): 439-445, 2013

NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model. Cancer Letters 414: 88-98, 2017

Effects of non-steroidal anti-inflammatory drug-activated gene-1 on Ganoderma lucidum polysaccharides-induced apoptosis of human prostate cancer PC-3 cells. International Journal of Oncology: -, 2018

Preparation and Anti-Cancer Evaluation of Promiximab-MMAE, an Anti-CD56 Antibody Drug Conjugate, in Small Cell Lung Cancer Cell Line Xenograft Models. Journal of Drug Targeting: 1-25, 2018

Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells. European Journal of Medicinal Chemistry 96: 259-268, 2016

Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. European Journal of Pharmacology 591(1-3): 43-51, 2008

Gellan gum nanohydrogel containing anti-inflammatory and anti-cancer drugs: a multi-drug delivery system for a combination therapy in cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics 87(1): 208-216, 2015

A novel anti-oxidant and anti-cancer strategy: a peptoid anti-inflammatory drug conjugate with SOD mimic activity. Biochemical and Biophysical Research Communications 317(4): 1155-1158, 2004